share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K：外国发行人报告（业绩相关）
美股sec公告 ·  06/26 14:14
Moomoo AI 已提取核心信息
Cybin Inc., a clinical-stage biopharmaceutical company, announced its fiscal year 2024 financial results and recent business highlights. The company reported significant progress with its two lead programs, CYB003 and CYB004, aimed at treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively. CYB003 received FDA Breakthrough Therapy Designation and is expected to enter Phase 3 trials in summer 2024. CYB004 has initiated a Phase 2 study. Cybin ended the fiscal year with C$209 million in cash and completed a U.S.$150 million oversubscribed private placement. The company's net loss increased year-over-year, with C$78 million reported for the fiscal year ended March 31, 2024. Cybin's CEO, Doug Drysdale, expressed optimism about the company's direction and the potential impact of its programs on mental health treatment. The company also strengthened its intellectual property portfolio with over 60 granted patents and more than 200 pending applications.
Cybin Inc., a clinical-stage biopharmaceutical company, announced its fiscal year 2024 financial results and recent business highlights. The company reported significant progress with its two lead programs, CYB003 and CYB004, aimed at treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively. CYB003 received FDA Breakthrough Therapy Designation and is expected to enter Phase 3 trials in summer 2024. CYB004 has initiated a Phase 2 study. Cybin ended the fiscal year with C$209 million in cash and completed a U.S.$150 million oversubscribed private placement. The company's net loss increased year-over-year, with C$78 million reported for the fiscal year ended March 31, 2024. Cybin's CEO, Doug Drysdale, expressed optimism about the company's direction and the potential impact of its programs on mental health treatment. The company also strengthened its intellectual property portfolio with over 60 granted patents and more than 200 pending applications.
临床阶段生物制药公司Cybin Inc.宣布其2024财年财务业绩和最新业务亮点。该公司报道称，其两个主要项目CYB003和CYB004取得了显著进展，分别旨在治疗重度抑郁症（MDD）和广泛性焦虑症（GAD）。CYB003获得FDA突破性疗法认定，并预计将于2024年夏季进入第3期临床试验。CYB004已启动2期研究。Cybin财年结束时现金余额为2.09亿加元，并完成了超额认购的1.5亿美元定向增发。公司净亏损同比增长，2024年3月31日结束的财年报告为7,800万加元。Cybin的首席执行官Doug Drysdale对公司的方向和其项目对心理健康治疗的潜在影响表示乐观。该公司还通过授权60多项专利和超过200个待批准申请加强了其知识产权组合。
临床阶段生物制药公司Cybin Inc.宣布其2024财年财务业绩和最新业务亮点。该公司报道称，其两个主要项目CYB003和CYB004取得了显著进展，分别旨在治疗重度抑郁症（MDD）和广泛性焦虑症（GAD）。CYB003获得FDA突破性疗法认定，并预计将于2024年夏季进入第3期临床试验。CYB004已启动2期研究。Cybin财年结束时现金余额为2.09亿加元，并完成了超额认购的1.5亿美元定向增发。公司净亏损同比增长，2024年3月31日结束的财年报告为7,800万加元。Cybin的首席执行官Doug Drysdale对公司的方向和其项目对心理健康治疗的潜在影响表示乐观。该公司还通过授权60多项专利和超过200个待批准申请加强了其知识产权组合。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息